New research shows that polygenic risk scores may enhance the prediction of non–small cell lung cancer (NSCLC) risk by highlighting key genetic mutations.
New research shows that polygenic risk scores may enhance the prediction of non–small cell lung cancer (NSCLC) risk by highlighting key genetic mutations.
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Developing a clinically meaningful immune-related adverse event (irAE) was associated with significantly improved overall survival in patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) treated with immune...
Learn about the crucial role of multidisciplinary team care coordination in improving outcomes for patients with early-stage non-small cell lung cancer, as discussed at AVAHO 2024, along with supporting research showing that MDT-based patient...
Learn about the crucial role of multidisciplinary team care coordination in improving outcomes for patients with early-stage non-small cell lung cancer, as discussed at AVAHO 2024, along with supporting research showing that MDT-based patient...
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
Progression-free survival was significantly longer with amivantamab–lazertinib compared with osimertinib as first-line treatment of untreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC),...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
A recent study highlights the significant impact of family tumor history on disease-free survival in patients with non-small cell lung cancer (NSCLC), suggesting that familial cancer backgrounds could be critical in tailoring treatment...
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
Despite promising early results, adding immunotherapy to standard chemotherapy does not significantly improve outcomes for patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after initial targeted therapy,...
